

PatientID: HDR7

Okitobba 06, 2023

### Color Code

■ HR: High-Level Resistance    ■ PLR: Potential Low-Level Resistance  
■ LR: Low-Level Resistance    ■ IR: Intermediate Resistance  
■ S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|------------|------|--------------------|----------------------------------|
| PI         | ATV  | S                  |                                  |
|            | DRV  | S                  |                                  |
|            | FPV  | S                  |                                  |
|            | IDV  | S                  |                                  |
|            | LPV  | S                  |                                  |
|            | NFV  | S                  |                                  |
|            | SQV  | S                  |                                  |
|            | TPV  | S                  |                                  |
| NRTI       | ABC  | PLR                | D67N;K70R                        |
|            | AZT  | IR                 |                                  |
|            | D4T  | IR                 |                                  |
|            | DDI  | LR                 |                                  |
|            | FTC  | S                  |                                  |
|            | LMV  | S                  |                                  |
|            | TDF  | PLR                |                                  |
| NNRTI      | DOR  | IR                 | P225H;K103N;E138A                |
|            | EFV  | HR                 |                                  |
|            | ETR  | PLR                |                                  |
|            | NVP  | HR                 |                                  |
|            | RPV  | LR                 |                                  |

## Appendix

### Drug abbreviations in full

| DRUG.CLASS   | ABBREVIATION | DRUG.NAME      |
|--------------|--------------|----------------|
| <b>PI</b>    | ATV          | Atazanavir     |
|              | DRV          | Darunavir      |
|              | FPV          | Fosamprenavir  |
|              | IDV          | Indinavir      |
|              | LPV          | Lopinavir      |
|              | NFV          | Nelfinavir     |
|              | SQV          | Saquinavir     |
|              | TPV          | Tipranavir     |
| <b>NRTI</b>  | ABC          | Abacavir       |
|              | AZT          | Azidothymidine |
|              | DFT          | Stavudine      |
|              | DDI          | Didanosine     |
|              | FTC          | Emtricitabine  |
|              | LMV          | Lamivudine     |
|              | TDF          | Tenofovir      |
| <b>NNRTI</b> | DOR          | Doravirine     |
|              | EFV          | Efavirenz      |
|              | ETR          | Etravirine     |
|              | NVP          | Nevirapine     |
|              | RPV          | Rilpivirine    |
| <b>INSTI</b> | BIC          | Bictegravir    |
|              | CAB          | Cabotegravir   |
|              | DTG          | Dolutegravir   |
|              | EVG          | Elvitegravir   |
|              | RAL          | Raltegravir    |

### Comments

| DRUG.CLASS   | COMMENTS  |
|--------------|---|
| <b>PI</b>    |   |
| <b>NRTI</b>  | D67N is a non-polymorphic TAM associated with low-level resistance to AZT.  |
|              | K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs.   |
| <b>NNRTI</b> | E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal. |
|              | K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.  |
|              | P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.                               |
| <b>INSTI</b> |   |